Last edition
News about "Mabylon AG"
Mabylon Advances Peanut Allergy Drug MY006 After Positive Early Clinical Data
Mabylon AG has reported positive preliminary Phase Ia results for MY006, its antibody-based peanut allergy treatment candidate, while also advancing a second allergy programme targeting tree pollen allergens.
Mabylon AG | 20/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members